Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 31.23 (2,500)
Ask (Size) 31.25 (400)
Prev. Close 31.25
Today's Range N/A - N/A
52wk Range 15.66 - 31.24
Shares Outstanding 266,264,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. 
Via InvestorPlace
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. 
Via Investor's Business Daily

Performance

More News

Read More
ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
Via Investor Brand Network
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
Via InvestorPlace
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
Via Benzinga
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
Via Get News
Exposures Product Safety
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
Via Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
Via News Direct
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
Via TheNewswire.com
Exposures Product Safety
ABBV: This Top Biotech Just Went On A Buying Spree
Via Talk Markets
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Via Investor's Business Daily
7 Dividend Aristocrats That Will Pay You for Years to Come
Via InvestorPlace
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
Via Investor's Business Daily
Cassava Sciences Stock Continues Showing Rising Relative Strength
Via Investor's Business Daily
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
Via Benzinga
Is AbbVie Stock a Buy Now?
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen, Inc.
Via Business Wire
3 Biotech Stocks Set for Breakthroughs in 2024
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Via MarketBeat
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.